万赛维疗效好吗？

It is the prodrug of ganciclovir and an active ganciclovir valine ester. After oral administration, it can be rapidly hydrolyzed into ganciclovir by phosphatase in intestinal and liver cells. Its antiviral spectrum and mechanism of action are similar to ganciclovir, but its bioavailability is significantly higher than that of ganciclovir. Its oral bioavailability is 62.4%, which is 10 times that of ganciclovir, while its toxicity is greatly reduced. In May 2001, it was approved by the US FDA for marketing. It is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome (AIDS). In May 2003, its indications were expanded to prevent and treat secondary CMV infection in organ transplant recipients.

Is Vancevi effective?

Clinical Evaluation: A randomized, open-label study compared the effectiveness of valganciclovir and ganciclovir induction in the treatment of newly infected AIDS-associated CMV retinitis. 160 patients were randomly treated with oral valganciclovir 900 mg or intravenous ganciclovir 5 mg·kg-1, bid, and then changed to qd after 3 weeks, and then treated for 1 week. After 4 weeks, all patients received oral valganciclovir (900 mg, qd) for maintenance treatment. The CD+4 cell count and highly active antiretroviral therapy (HAART) status of patients in each group before treatment were similar. The first endpoint of induction therapy is the progression of CMV retinitis at 4 weeks of treatment, and the second endpoint is the progression time of CMV retinitis and the achievement of satisfactory efficacy. The number of patients with progression of CMV retinitis was similar in the oral valganciclovir group and the intravenous ganciclovir group, at 10%. The median time to disease progression in the oral valganciclovir group was longer than that in the intravenous ganciclovir group, 160 d and 125 d respectively, while the mean time to disease progression was similar, 226 d and 219 d respectively. Oral valganciclovir and intravenous ganciclovir induction therapy achieved similar rates of satisfactory efficacy at 4 weeks, 72% and 77% respectively. Analysis of subgroup data including CD+4 cell count, CD+4 cell count increase and HAART at the start of treatment and 4 weeks after treatment showed that the efficacy of valganciclovir and ganciclovir was similar.